Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddys launches OTC...

    Dr Reddys launches OTC brand equivalent of Mucinex D ER tablets to treat phlegm

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-10T10:04:04+05:30  |  Updated On 17 Aug 2021 1:00 PM IST

    The Mucinex D brand and store brands had combined US sales of approximately USD 71 million MAT (moving annual turnover) for the most recent 12 months ending May 2019, the release said quoting market reports, the release said.


    Hyderabad: Dr Reddys Laboratories Ltd (DRL) recently announced the launch of an over-the-counter (OTC) store-brand equivalent of Mucinex D extended-release tablets in two strengths.


    The OTC Guaifenesin and Pseudoephedrine HCl is used to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus, a press release from the company said.


    "We are excited to bring first to the market the store-brand equivalent of Mucinex D maximum strength extended-release tablets. The launch illustrates our continued commitment to the OTC business and our growing portfolio in the cough, cold and allergy category," Milan Kalawadia, senior vice-president and head of US (OTC and speciality Rx divisions), Dr Reddys, said in the release.


    Read Also: Dr Reddy's Laboratories to buy IP rights of fondaparinux for $17.5 million


    The Mucinex D brand and store brands had combined US sales of approximately USD 71 million MAT (moving annual turnover) for the most recent 12 months ending May 2019, the release said quoting market reports, the release said.


    The OTC product is available as Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg and Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg strengths, it said.


    Dr Reddy's OTC Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg is available in 24-count packages while OTC Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg is available in 18- and 36-count packages.


    Dr Reddy's Labs offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. The major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.


    Read Also: Awaiting USFDA response on remediation efforts of 3 units: Dr Reddys Laboratories

    allergyantiphlegmbronchial secretionsCardiovascularcoldcoughDermatologydiabetologyDr Reddy'sDr Reddy's LaboratoriesDr Reddy's LabsgastrointestinalGuaifenesinMucinex DMucinex D ER tabletsmucusoncologyOTC drugpain managementphlegmPseudoephedrine

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok